Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Marketing Surveillance (Usage Results Study) of LIVTENCITY Tablet (Maribavir) for the Approved Indications in South Korea

NCT06555432 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06555432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06555432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Marketing Surveillance (Usage Results Study) of LIVTENCITY Tablet (Maribavir) for the Approved Indications in South Korea
Lead sponsor
Takeda
Phase
Observational
Overall status
Recruiting
Start date
November 14, 2024
Completion date
October 1, 2028
Enrollment
168 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus (cmv)